Artelo Biosciences, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ARTL | EOCN | CANF | SILO | EDVA | MTVA | |
|---|---|---|---|---|---|---|
| Market cap | 1.70M | 3.44M | 5.91M | 3.06M | 1.62M | 9.55M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -3.5 | — | -2.1 | -2.1 | — | — |
| Price/book | 0.3 | 0.3 | 0.9 | 0.3 | 0.0 | 1.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −97.08% | −69.90% | −81.37% | −84.39% | −98.15% | −87.07% |
| Today | −4.60% | −9.04% | +2.63% | +1.36% | −6.41% | +2.84% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ARTL news ›Artelo Biosciences flagged under Nasdaq $5M MVLS rule; monitoring options to regain compliance
TradingView Artelo Biosciences flagged under Nasdaq $5M MVLS rule; monitoring options to regain compliance Artelo Biosciences disclosed it was identified as below Nasdaq's new $5M MVLS threshold and is evaluating options to regain…
Artelo Biosciences initially below $5M Nasdaq threshold
Nasdaq initially identified Artelo among companies below the $5 million market-value threshold; the rule is under a temporary stay, and the filing says the stay’s duration and the rule’s final form remain unknown. Pursuant to Section 13 OR…
Artelo Biosciences Announces Reverse Stock Split
SOLANA BEACH, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage p... Artelo Biosciences Announces Reverse Stock Split SOLANA BEACH, Calif., Aug. 27, 2026 (GLOBE…
Artelo Biosciences Inc trading halted, news pending
19:50 EDT Artelo Biosciences (ARTL) Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-movi... Artelo Biosciences Inc trading halted, news pending 19:50 EDT Artelo Biosciences (ARTL) Inc…
Artelo Biosciences announces results from nonclinical study of ART27.13
Artelo Biosciences (ARTL) announced results from a nonclinical study of ART27.13, its oral, once-daily, peripherally selective dual cannabinoid ... Artelo Biosciences announces results from nonclinical study of ART27.13 Artelo Biosciences…
Artelo Biosciences files new provisional patent application covering ART27.13
Artelo Biosciences (ARTL) announced the filing of a provisional patent application covering the use of ART27.13 for the treatment of obesity. Th... Artelo Biosciences files new provisional patent application covering ART27.13 Artelo…
Artelo Biosciences Inc Registered Shs Stock , ARTL
The latest Artelo Biosciences stock prices, stock quotes, news, and ARTL history to help you invest and trade smarter. Artelo Biosciences Inc Registered Shs Stock , ARTL Artelo Biosciences Stock Snapshot Artelo Biosciences News More News…
Why Is Penny Stock Artelo Biosciences (ARTL) Up Over 200% Today?
Artelo Biosciences (ARTL) stock rocketed over 200% on Wednesday after the clinical-stage biopharmaceutical company announced a new patent update in a press release. The company said it had filed a patent application for using ART27.13 to…
Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies
The Patent Claims are for the Intended Commercial Formulation of ART27.13 Expected to Extend Patent Protection for ART27.13 through 2041 SOLANA BEACH, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Artelo ... Artelo Biosciences Receives a…
Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings
As reported, ART27.13 produced approximately 40% weight loss in combination with semaglutide and approximately 20% as monotherapy, comparable to semaglutide, in obese mice over four weeks Application expands Artelo’s intellectual property…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
marketscreener.com11
-
markets.businessinsider.com9
-
stocktitan.net2
-
tradingview.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 23 articles, not a forecast.